827 related articles for article (PubMed ID: 17113714)
1. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
Kirchheiner J; Seeringer A
Biochim Biophys Acta; 2007 Mar; 1770(3):489-94. PubMed ID: 17113714
[TBL] [Abstract][Full Text] [Related]
2. Applications of CYP450 testing in the clinical setting.
Samer CF; Lorenzini KI; Rollason V; Daali Y; Desmeules JA
Mol Diagn Ther; 2013 Jun; 17(3):165-84. PubMed ID: 23588782
[TBL] [Abstract][Full Text] [Related]
3. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics-guided dose modifications of antidepressants.
Seeringer A; Kirchheiner J
Clin Lab Med; 2008 Dec; 28(4):619-26. PubMed ID: 19059066
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacogenetics and potential application in personalized medicine.
Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.
Kirchheiner J; Nickchen K; Bauer M; Wong ML; Licinio J; Roots I; Brockmöller J
Mol Psychiatry; 2004 May; 9(5):442-73. PubMed ID: 15037866
[TBL] [Abstract][Full Text] [Related]
7. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.
Rogers JF; Nafziger AN; Bertino JS
Am J Med; 2002 Dec; 113(9):746-50. PubMed ID: 12517365
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics.
Quaranta S; Dupouey J; Colle R; Verstuyft C
Therapie; 2017 Apr; 72(2):311-318. PubMed ID: 28237405
[TBL] [Abstract][Full Text] [Related]
10. [CYP2D6-, CYP2C9- and CYP2C19-based dose adjustments: when do they make sense?].
Seeringer A; Kirchheiner J
Internist (Berl); 2008 Jul; 49(7):877-83. PubMed ID: 18551264
[TBL] [Abstract][Full Text] [Related]
11. Polymorphic drug metabolizing CYP-enzymes--a pathogenic factor in oral lichen planus?
Kragelund C; Hansen C; Reibel J; Nauntofte B; Broesen K; Pedersen AM; Smidt D; Eiberg H; Torpet LA
J Oral Pathol Med; 2009 Jan; 38(1):63-71. PubMed ID: 19192051
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of drug metabolising enzymes: importance for personalised medicine.
Oscarson M
Clin Chem Lab Med; 2003 Apr; 41(4):573-80. PubMed ID: 12747605
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Bauer S; Rohde W; Meisel C; Roots I; Brockmöller J
Clin Pharmacokinet; 2004; 43(4):267-78. PubMed ID: 15005635
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.
Wang B; Wang J; Huang SQ; Su HH; Zhou SF
Curr Drug Metab; 2009 Sep; 10(7):781-834. PubMed ID: 19925388
[TBL] [Abstract][Full Text] [Related]
15. Increasing relevance of pharmacogenetics of drug metabolism in clinical practice.
Pillans PI
Intern Med J; 2001 Nov; 31(8):476-8. PubMed ID: 11720061
[TBL] [Abstract][Full Text] [Related]
16. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
Zhou SF; Liu JP; Chowbay B
Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic prediction of individual variability in drug response based on CYP2D6, CYP2C9 and CYP2C19 genetic polymorphisms.
Chaudhry SR; Muhammad S; Eidens M; Klemm M; Khan D; Efferth T; Weisshaar MP
Curr Drug Metab; 2014; 15(7):711-8. PubMed ID: 25429673
[TBL] [Abstract][Full Text] [Related]
18. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
Topić E; Stefanović M; Samardzija M
Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
[TBL] [Abstract][Full Text] [Related]
19. Clinical application of cardiovascular pharmacogenetics.
Voora D; Ginsburg GS
J Am Coll Cardiol; 2012 Jul; 60(1):9-20. PubMed ID: 22742397
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system.
Ingelman-Sundberg M; Sim SC
Biochem Biophys Res Commun; 2010 May; 396(1):90-4. PubMed ID: 20494117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]